Risk factors
Hepion Pharmaceuticals (HEPA) risk factors
Item 1A of every Hepion Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
50 risks, 11 new, 16 dropped, 3 reworded since the prior year. Accumulated deficit increased to $246.1 million for the year ended December 31, 2025.
Filed Mar 12, 2026 - FY2024 10-K risk factors
55 risks. Hepion Pharmaceuticals faces substantial accumulated deficits and requires significant additional capital to fund ongoing clinical development. The company relies heavily on third-party contract manufacturers for rencofilstat and lacks internal sales or discovery capabilities. Extensive FDA and foreign regulatory compliance, potential clinical trial delays, and intense biopharmaceutical competition dominate its risks.
Filed Apr 08, 2025